Atrovent Hfa is owned by Boehringer Ingelheim.
Atrovent Hfa contains Ipratropium Bromide.
Atrovent Hfa has a total of 1 drug patent out of which 0 drug patents have expired.
Atrovent Hfa was authorised for market use on 27 November, 2004.
Atrovent Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Atrovent Hfa are possible to be released after 17 January, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8474447||BOEHRINGER INGELHEIM||Inhaler device|| |
(6 years from now)
Market Authorisation Date: 27 November, 2004
Dosage: AEROSOL, METERED;INHALATION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic